

## **RBC LIFE SCIENCES RETAINS HALLIBURTON INVESTOR RELATIONS TO DIRECT IR PROGRAM**

Irving, Texas (January 9, 2007) – **RBC Life Sciences, Inc. (OTCBB: RBCL)**, a manufacturer and marketer of skin care products and nutritional supplements, today announced it has retained Dallas-based [Halliburton Investor Relations](#) to manage the Company's investor relations program.

Halliburton Investor Relations will focus on promoting investor awareness of the Company's financial performance, assisting with communicating its growth strategy and broadening the Company's institutional shareholder base.

[Clinton Howard](#), Chairman and CEO of RBC Life Sciences, said, "Over the past year the rise in market value of RBC stock reflects the improved sales and earnings of RBC, most of which was attributable to expanding international sales and increased domestic sales of medical wound and oncology products." Mr. Howard further commented, "Halliburton Investor Relations' wide-ranging and proven investor relations program will enable us to communicate our achievements and broaden our visibility with the investment community."

Geralyn DeBusk, President of Halliburton Investor Relations, said, "RBC Life Sciences is an inventive company, pioneering new ways to ensure people live healthier lives. The company has a history of success, yet remains relatively undiscovered by the investment community. We believe RBC's future growth opportunities, and its innovative product line, make it a prime candidate for our strategic investor relations program."

**Contact:** Jeff Elliott or Chase Zavoina  
Halliburton Investor Relations  
972-458-8000

### **About RBC Life Sciences**

RBC Life Sciences develops, manufactures and markets skin care products and food supplements providing nutrients often found to be low or missing in modern diets. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed.

MPM Medical, a wholly owned subsidiary of RBC, develops and markets proprietary prescription and nonprescription products for wound and pain management, sold through medical-surgical dealers to nursing homes, hospitals and cancer clinics. For more information on the company, visit [www.RBCLifeSciences.com](http://www.RBCLifeSciences.com).

### **About Halliburton Investor Relations**

Halliburton Investor Relations was formed in 1990 to provide a superior caliber of investor relations representation to publicly traded companies. HIR develops strategic communications programs designed to produce maximum results. Cultivating highly targeted, quality contacts in the financial community, HIR puts its clients face-to-face with hand-picked potential investors and influencers, the product of a highly selective research process. For more information on the company, visit [www.HalliburtonIR.com](http://www.HalliburtonIR.com).

*This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements involve risk and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Factors that could contribute to such differences are disclosed in the Company's annual report on Form 10-K, quarterly reports on Form 10-Q, and other reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates and expectations as of the date of the press release, and subsequent events and developments may cause the Company's estimates and expectations to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates and expectations of its future financial performance as of any date subsequent to the date of this press release.*